Prof. Nusrat Husain

Co-Applicant - Moving on ABC

Professor Nusrat Husain is a Professor of Psychiatry and Director of Research for Global Mental Health at the University of Manchester. Additionally, he is an Honorary Clinical Professor at the University of Liverpool, a Visiting Clinical Professor at the University of Bolton, a Consultant Psychiatrist, and the Director of the Global Centre for Research on Mental Health Inequalities at Mersey Care NHS Foundation Trust.

He is also an executive member of the Academic Faculty at the Royal College of Psychiatrists, London, the past president of the Manchester Medical Society, and an NIHR Senior Investigator.

His research focuses on addressing the mental health treatment gap in low and middle-income countries and mental health disparities among ethnic minorities in high-income countries. He leads applied research programmes to reduce self-harm, prevent suicide, and address mental health inequalities.

With collaborators in Pakistan, Canada, Brazil, and Kenya, Nusrat is known for his work on culturally adapted psychosocial therapies and innovative pharmacological treatments for mental illness. His research has had a significant impact on policy.

He jointly organised the First All Parliamentary Summit hosted by the President of Pakistan and contributed to the development of substance use mental health policy. Most recently, he also helped launch the suicide prevention strategy 2025-2030 in Sindh, Pakistan.

He has led multiple externally funded projects supported by organisations such as the Medical Research Council, Wellcome Trust, National Institute for Health and Care Research (NIHR), Stanley Medical Research Institute, Canadian International Development Agency, British Council, and Grand Challenges Canada.

Professor Nusrat Husain’s most recent NIHR-funded projects include:

  • The Affordable Cardiac Rehabilitation Study (ACROSS),
  • The Integrated Psychosocial Care Plan for Comorbid Depression in Breast Cancer Patients in Low Resources Settings, and
  • A randomised controlled trial on quetiapine for people with borderline personality disorder.